Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA

Executive Summary

The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains

You may also be interested in...



Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials

Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials

Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data

FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel